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Random transposon mutagenesis allows relatively rapid, genome-wide surveys to 2 
detect genes involved in functional traits, by performing screens of mutant libraries. 3 
This approach has been widely applied to identify genes responsible for activities of 4 
interest in multiple eukaryote and prokaryote organisms, although most studies on 5 
microorganisms have focused on pathogenic and clinically relevant bacteria. In this 6 
chapter we describe the implementation of an in vitro Tn5-based transposome 7 
strategy to generate a large collection of random mutants in the gut commensal 8 
Bifidobacterium breve UCC2003, and discuss considerations when applying this 9 
mutagenesis system to other Bifidobacterium species/strains of interest. 10 






1. Introduction 1 
Bifidobacteria are Gram-positive commensal microorganisms whose presence in the 2 
human gastrointestinal tract has been associated with beneficial effects on host health 3 
(1). Consequently, significant scientific and commercial efforts have been made to 4 
discern the mechanisms responsible of their purported beneficial attributes and cross-5 
talk with the human host and with other members of the intestinal microbiota (2). In 6 
this context, gene inactivation may be considered to represent the gold standard 7 
methodology to unequivocally prove the function of specific genes although most 8 
Bifidobacterium strains remain recalcitrant to genetic manipulation with only a few 9 
species and strains having been successfully mutated to date (3–6). An increasing 10 
number of genome-based studies has allowed insights into the reasons why genetic 11 
manipulation of this group of commensal microorganisms is so difficult, and has 12 
provided new opportunities to design tailor-made tools to achieve gene inactivation in 13 
various Bifidobacterium species/strains (4, 5, 7–10). 14 
Transposon-based random mutagenesis approaches generally involve the in vivo 15 
delivery of a conditional vector carrying a transposon piece of DNA containing a 16 
selective marker (usually an antibiotic resistance cassette) and the transposase 17 
encoding gene. Tight control of transposase expression allows for the transposon to 18 
jump into (random positions in) the targeted genome, thereby inactivating any gene in 19 
which it had been inserted. Subsequent plasmid curing, which removes the 20 
transposase-encoding gene from the cells, fixes the transposon in the original insertion 21 





number of transposon insertion mutants from a single transformant carrying the 1 
delivery vector. However, substantial limitations exist to apply such an approach in 2 
bifidobacteria as conditional replicative vectors are currently not available for most 3 
species/strains. Besides, most heterologous expression systems in bifidobacteria have 4 
made use of strong constitutive promoters, which are not appropriate to control the 5 
expression of a transposase as high expression of a transposase in the presence of the 6 
corresponding transposon, may destabilize the transposon position and ultimately 7 
affect cell viability. An alternative to this in vivo transposon delivery approach was 8 
proposed early in 2002 when certain mobile genetic elements, i.e. Tn5 and Mu 9 
transposons, were shown to form functional transposon-transposase complexes by 10 
means of in vitro assembly. These complexes were reported to be stable enough to be 11 
directly electroporated into the targeted host, where they successfully transposed into 12 
the host DNA (12, 13). The practical implementation of this system to new strains 13 
requires achieving: (i) high transformation efficiencies in the selected host, and (ii) the 14 
use of an appropriate antibiotic selection marker within the transposon as it needs to 15 
be efficiently expressed to confer antibiotic resistance so as to allow selection for 16 
(single-copy) transposon insertion events. The development of these in vitro 17 
transposon delivery approaches represented a huge advancement as they offered new 18 
opportunities to tackle transposon-based random mutagenesis in microorganisms, 19 
such as bifidobacteria.  20 





2.1. Materials and equipment for molecular biology techniques used for transposon 1 
construction, purification and assembly; and for identifying transposon insertion 2 
points in the mutants obtained 3 
1. Standard molecular biology reagents (see Note 1): PCR master mix; appropriate 4 
restriction enzymes for transposon end pruning (PshAI or PvuII if using pMOD2-TetW), 5 
and, if relevant, for cloning a new antibiotic resistance cassette in between the Tn5 6 
mosaic ends to create a new transposon (see Note 2); plasmid mini-preparation kits to 7 
conduct plasmid extraction from bacterial cultures ; PCR purification kits; agarose, 1X 8 
TAE buffer (40 mM Tris-HCl pH 7.6, 20 mM acetic acid, 1 mM EDTA), ethidium 9 
bromide. 10 
2. Replicative vector containing an antibiotic resistant Tn5 transposon, e.g. pMOD2-11 
TetW from Ruiz et al. (14) or, alternatively, another customized transposon (see Note 12 
2). This vector will be used as a source of the transposon piece of DNA and can be 13 
stably maintained into appropriate host cells as it does not contain the transposase-14 
encoding gene (and therefore will not destabilize the transposon piece of DNA). If 15 
using pMOD2-TetW, most E. coli cloning hosts are capable to support its replication, 16 
although endA- strains are recommended in order to achieve high plasmid yields (see 17 
Note 3). 18 
3. Oligonucleotides to amplify the Tn5 transposon from the replicative vector into 19 
which it is being maintained (e.g. pMOD2-TetW). If using pMOD2-TetW, 20 





GTCAGTGAGCGAGGAAGCGGAAG-3') can be used as previously described (Ruiz et al., 1 
2013). 2 
3. Purified EZ-Tn5 transposase (commercially available by Lucigen Corporation, 3 
Middleton, WI, US - www.lucigen.com -), it is a mutated version of the original Tn5 4 
transposase that displays a transposition frequency which is 1,000 fold higher than the 5 
one exhibited by the original Tn5 transposase. 6 
4. Molecular grade glycerol. 7 
2.2. Microbiology reagents for culturing bacteria 8 
1. Luria Bertani (LB) culture media: 10 g L-1 tryptone (Merck, Darmstadt, Alemania), 5 g 9 
L-1 yeast extract (Merck), 10 g L-1 sodium chloride (Merck), sterilized by autoclaving. 10 
This medium will be used for routinely growth of E. coli cells or, supplemented with 10 11 
μg ml-1 tetracycline in order to select for E. coli strains harbouring pMOD2-TetW.  12 
2. de-Man-Rogosa-Sharpe (MRS) adjusted to pH 6.8: Proteose Peptone (10 g L-1) (Difco, 13 
Franklin Lakes, NJ, US), beef extract (10 g L-1) (Difco), yeast extract (5 g L-1) (Difco), 14 
polysorbate (tween 80) (1 ml L-1) (Sigma Aldrich; St Louis, MO, US), tri-ammonium 15 
citrate (2 g L-1) (Sigma Aldrich), magnesium sulfate heptahydrated (0.525 g L-1) (Merck), 16 
manganese sulfate tetrahydrated (0.12 g L-1) (Merck), di-potassium phosphate (3 g L-1) 17 
(Merck), potassium phosphate (3 g L-1) (Merck), pyruvic acid (0.2 g L-1) (Sigma Aldrich), 18 
cysteine-HCl (0.3 g L-1) (Sigma Aldrich), ferric sulphate heptahydrate (0.034 g L-1) 19 





appropriate Bifidobacterium strain for competent cell preparation prior to 1 
electroporation. 2 
3. 10 % D-Lactose solution prepared in distilled water and sterilized by filtration (0.2 3 
μm diameter pore) (see Note 4). 4 
4. 10 % L-cysteine-HCl solution prepared in distilled water and sterilized by filtration 5 
(0.2 μm diameter pore). 6 
5. Washing buffer for preparation of electrocompetent cells of Bifidobacterium: 1 mM 7 
citrate, 0.5 M sucrose buffer, pH 5.8, sterilized by autoclaving. 8 
6. Reinforced Clostridial Medium (RCM) (Oxoid) for routine growth of Bifidobacterium 9 
cells, resuscitation and recovery of electrotransformed cells. 10 
7. Reinforced Clostridial Agar (RCA) (Oxoid) plates supplemented with appropriate 11 
antibiotic concentrations for transposon insertion selection. In the particular case of 12 
using the Tn5-TetW transposon described for B. breve UCC2003 or B. breve NCFB2258 13 
strains (14), use a final concentration of 10 μg ml-1 of tetracycline (see Note 5). 14 
8. 10 mg ml-1 tetracycline stock solution dissolved in 50 % ethanol and sterilized by 15 
filtration (0.2 μm diameter pore). The filtered sterilized stock solution can be stored at 16 
-20ºC (see Note 6). 17 
9. Plasmid capable of replicating into the selected Bifidobacterium host, preferably 18 
harbouring the same antibiotic resistance cassette than the transposon, to be used as 19 





using pMOD2-TetW, the E.coli-Bifidobacterium shuttle vector pAM5 (15) can be used 1 
as a control plasmid. 2 
2.3. Other equipment required 3 
1. Thermocycler. 4 
2. Microcentrifuge. 5 
3. Electroporator and electroporation cuvettes. 6 
4. Device for spectrophotometric DNA quantification, e.g. Nanodrop or Qubit systems 7 
5. Electrophoresis unit and transilluminator for DNA visualization. 8 
6. Rotatory shaker incubator 9 
7. Anaerobic work station (10 % H2, 10 % CO2, 80 % N2). 10 
8. Refrigerated centrifuge with rotor for bottles of at least 50 ml volume. 11 
3. Methods 12 
A schematic overview of the main steps which are detailed in the following sections is 13 
represented in Figure 1. 14 
3.1. Transposon construction and preparation 15 
1. A customized transposon can be constructed by cloning the desired antibiotic 16 
resistance cassette, or any alternative selective marker to identify transposon insertion 17 





and Reznikoff, 1983) in an E. coli replicative vector (e.g. pMOD2 vector from Lucigen) 1 
(Figure 1). The tetW resistance cassette used in pMOD2-TetW was originally isolated 2 
from a Bifidobacterium species (17) and has been shown to be efficiently expressed to 3 
provide sufficient tetracycline resistance in order to achieve selection of clones 4 
harbouring a single chromosomal copy of the corresponding gene in multiple 5 
Bifidobacterium strains (4, 9). For the above reasons, this is a good marker to be 6 
included in a transposon to be used in tetracycline-sensitive Bifidobacterium strains 7 
(14).  8 
2. Plasmid mini-preparations from the transposon containing construct (e.g. pMOD2-9 
TetW or alternative customized constructs as indicated in Note 2) will be used to 10 
generate large quantities of a TetW-Tn5 transposon ready for assemblage with the 11 
purified EZ-Tn5 transposase. Plasmid miniprep extractions need to be performed on E. 12 
coli cells harbouring the transposon-containing plasmid (e.g. pMOD2-TetW). An 13 
appropriate volume of growing cells must be used according to guidelines of the 14 
plasmid mini-preparation kit provider. Extracted plasmid DNA must be verified by 15 
restriction profiling followed by agarose gel electrophoresis. For instance, to verify the 16 
pMOD2-TetW construct, digest 10 µl of a plasmid mini-preparation in a final reaction 17 
volume of 20 µl by using SphI and XbaI according to indications from the restriction 18 
enzymes provider. Following incubation for at least 1 hour at 37ºC, mix 10 μl of 19 
restricted plasmid DNA with 2 μl of commercial loading buffer dye and load on a 1 % 20 
agarose gel. Apply a voltage of 1.5 V/cm until the dye reaches about two thirds of the 21 
gel length; and stain the gel for 30 minutes with ethidium bromide (0.5 μg ml-1). 22 





should be visible as bright bands of 2.5 Kb (pMOD2 backbone) and 2.8 Kb (tetracycline 1 
resistance Tn5 transposon). 2 
3. PCR-amplify the transposon piece of DNA using as a template the plasmid mini-3 
preparation of the construct harbouring it, e.g. pMOD2-TetW, isolated from E. coli cells 4 
in the previous step. Oligonucleotides annealing immediately upstream of the inverted 5 
repeats flanking the Tn5 transposon in the plasmid harbouring the transposon must be 6 
used. If using a transposon constructed within a pMOD2 vector, as the one described 7 
above for bifidobacteria, oligonucleotides pMOD<MCS>Fw and pMOD<MCS>Rev 8 
(Lucigen) can be used. A suggested PCR cycling scheme is as follows: (i) denature the 9 
template at 94°C for 2 minutes; (ii) perform 30 cycles denaturing at 94°C for 30 10 
seconds; annealing at 60°C for 45 seconds and extending at 72°C for 1 minute for every 11 
kb of expected product. Since a good amount of transposon DNA needs to be 12 
generated, it is recommended to perform at least 5-10 PCR reactions in a final volume 13 
of 50 μl each to guarantee a sufficiently large quantity of transposon DNA (as a general 14 
guideline, it would be recommended to generate at least 50-60 μg of PCR product).  15 
3. To verify that PCR reactions have amplified a fragment of the desired size, load 5 μl 16 
of the PCR reactions in a 1 % agarose gel as previously described in step 2. The TetW-17 
Tn5 transposon from Ruiz et al. (14) should produce a band of about 2.8 kb. Each PCR 18 
product must be purified on a silica column (see Note 7).  19 
4. The efficiency of the transposition process is maximized in the presence of 20 
phosphorylated transposon ends. In order to get phosphorylated ends, the TetW-Tn5 21 





pruned by restriction with PshAI or PvuII, as these restriction sites are located 1 
immediately upstream of the transposon inverted repeats. The restriction reactions 2 
must be set up according to guidelines issued by the restriction enzyme provider (see 3 
Note 8). Following restriction, the transposon is cleaned up using a column PCR 4 
purification system and each DNA preparation is concentrated by eluting it in a small 5 
volume in the final step of the cleaning procedure (20 μl per purification column).  6 
5. Pool all transposon preparations and measure DNA concentration for instance using 7 
spectrophotometric methods (e.g. nanodrop or Qubit based nucleic acid 8 
quantification). The concentration of transposon ends need to be adjusted to desired 9 
values taking into consideration the transposon length, by following instructions from 10 
the Tn5 transposase provider. The TetW-Tn5 transposon previously used for 11 
bifidobacteria was adjusted to a final concentration of 400 ng μl-1. 12 
6. The transposon-transposase complexes are assembled according to instructions 13 
from the transposase provider. As a standard guideline, mix 2 μl of transposon DNA 14 
preparation (dissolved in TE Buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA)); 4 μl of EZ-15 
Tn5 transposase (1 U/μl) and 2 μl of 100 % glycerol, vortex and incubate at room 16 
temperature for 30 minutes. This preparation can be directly electroporated into 17 
freshly prepared Bifidobacterium competent cells, or stored at -20 ºC until use. 18 
7. Assembled transposome complexes can then be electroporated into freshly 19 
prepared Bifidobacterium electrocompetent cells by following the instructions 20 





3.2. Preparation of electrocompetent cells of Bifidobacterium 1 
In order to achieve maximum transformation efficiencies, electroporation needs to be 2 
conducted employing freshly prepared Bifidobacterium competent cells. Growth 3 
media, wash buffer and antibiotic containing plates are recommended to be prepared 4 
freshly the day before the experiment starts.  5 
DAY 1 6 
1. An isolated colony of the strain to be mutated is inoculated into 10 ml of RCM broth 7 
and grown overnight (~16 hours) at 37ºC in standing tubes into an anaerobic chamber 8 
(10 % CO2, 10 % H2, 80 % N2 atmosphere).  9 
2. 50 ml tubes containing de Man-Rogosa-Sharpe broth supplemented with a final 10 
concentration of 0.05 % L-cysteine (freshly added from a 10 % filter sterilized stock 11 
prepared in distilled water); and 1 % of an appropriate carbon source (for B. breve 12 
UCC2003 or B. breve NCFB2258, use D-lactose freshly added from a 10 % filter 13 
sterilized stock solution prepared in distilled water) can be pre-reduced and stored 14 
overnight in the same anaerobic chamber. 15 
DAY 2 16 
2. The pre-reduced and pre-warmed de Man-Rogosa-Sharpe broth supplemented with 17 
the carbon source and L-cysteine, is inoculated (2 % v/v) with the culture grown 18 
overnight. Incubate the standing tubes at 37ºC in the anaerobic chamber until the 19 





3. While the culture(s) for competent cell preparation are growing, the citrate-sucrose 1 
buffer must be placed in an ice box and an appropriate centrifuge, 1.5 ml eppendorf 2 
tubes, pipettes and electroporation cuvettes must be refrigerated by keeping them in 3 
an ice box. 4 
4. Incubate cultures for competent cells preparation until they reach an optical density 5 
at 600 nm between 0.5-0.7 (5-7 hours). At this point, take the cultures out of the 6 
anaerobic incubator and spin down the cells at 4 000 g in a cold rotor (4ºC) for 10 7 
minutes. From this point onwards the cells need to be kept ice-cold. 8 
5. Wash the cells twice by decanting the supernatant and gently swirling the cell pellet 9 
into the same volume (50 ml) of ice-cold 1 mM citrate-0.5 M sucrose buffer. 10 
6. Resuspend the washed cell pellet obtained from 50 ml of culture into 500 μl of ice-11 
cold citrate-sucrose buffer.  12 
7. In 1.5 ml eppendorf tubes dispense adequate amounts of Tn5 transposase-13 
transposon complexes assembled as previously described in section 1. In parallel, in 14 
one of the tubes add 5 μl of a plasmid capable of replicating into the Bifidobacterium 15 
strain used, e.g. pAM5 (15), in order to be used as a positive control to verify the 16 
quality of the prepared competent cells and Bifidobacterium electrotransformation 17 
procedure. 18 
8. Add to each tube containing the transposase-transposon complexes or positive 19 





pipetting up and down and transfer the whole volume to an ice cold electroporation 1 
cuvette (see Note 9). 2 
9. Apply a pulse of 2.0 KV, 200 ohms, 25 μF in an electroporator (e.g. Gene Pulser II 3 
Porator Electroporation System from Bio Rad). Immediately following application of 4 
the electric pulse, aseptically add 950 μl of RCM and gently suspend the cells by 5 
pipetting up and down a few times. 6 
10. Incubate the electroporation cuvettes with the cell suspensions for 30 minutes at 7 
37ºC in the anaerobic incubator (see Note 10). 8 
11. Plate 100 μl aliquots of electroporated cells onto freshly prepared plates of RCA 9 
supplemented with 10 μg ml-1 of tetracycline added from a filter-sterilized 1000X stock 10 
solution as previously described (section 2.2). 11 
12. Incubate the plates anaerobically at 37ºC for 2-3 days. 12 
2.3. Recovery of tetracycline-resistant colonies and identification of transposon 13 
insertion sites 14 
If no antibiotic resistant colonies are grown following electroporation of transposome 15 
complexes, verify the presence of antibiotic resistant colonies in the reaction 16 
performed with the positive control plasmid DNA. If transformation efficiency of this 17 
control plasmid is under 104 cfu μg-1, repeat the experiment or consider optimizing the 18 





If (sufficient) antibiotic resistant colonies are grown following electroporation of 1 
transposome complexes: 2 
1. Using a sterile pipette tip, inoculate them into RCM broth supplemented with 3 
tetracycline (10 μg ml-1) and cultivate them overnight anaerobically at 37ºC. 4 
2. The following day, add 30 % sterile glycerol and stock the clones at -80ºC for further 5 
analysis. 6 
3. The transposon presence in obtained clones can be verified through a) Southern blot 7 
hybridization; b) PCR using oligonucleotides targeting the transposon mosaic ends or 8 
targeting internal sequence fragments within the transposon. 9 
4. Identification of transposon insertion sites in specific clones can be performed 10 
through inverse-PCR coupled to Sanger sequencing as previously described (14) (see 11 
Note 12). As a general guideline, the inverse-PCR procedure to identify the genome 12 
positions where a transposon is inserted in a specific clone includes the following 13 
steps: 1) extract Bifidobacterium DNA (see Note 13); 2) digest 1 μg of DNA in a final 14 
volume of 50 μl of reaction, using a restriction enzyme which does not cut within the 15 
transposon; 3) purify digested DNA; a suggested protocol is as follows: add 50 μl of 16 
distilled water and 100 μl of phenol/chloroform pH 8.0, mix and spin down (≥ 12 000 g, 17 
10 minutes), transfer upper phase to a fresh tube, add 1/10 volumes of sodium acetate 18 
3 M pH 5.8 and 1 volume of cold ethanol; spin down 30 minutes, ≥ 12 000 g, 4ºC; 19 
remove supernatant; wash with 70 % ethanol; air dry and resuspend in 10 μl of 20 





reactions, using 0.2 or 0.4 μg of restricted DNA in a final volume of 50 μl; 6) incubate 1 
ligations overnight at room temperature; 7) purify ligated DNA using the same 2 
procedure described in step 3; 8) set up PCR reactions using each ligation reaction as 3 
template DNA and oligonucleotides annealing with the transposon ends, outwards 4 
facing (if using the TetW-Tn5 previously used for bifidobacteria, the oligonucleotides i-5 
PCR-Fw 5'- GCATACCGTACTGATCTG-3' and i-PCR-Rev 5'-CAATCATACCGGCTTCC-3' can 6 
be used) (see Note 14); 9) verify the PCR amplification by loading 5 μl in a 1 % agarose 7 
gel as previously described (section 3.1. step 2); 10) sequence the PCR products using 8 
nested oligonucleotides, located within the transposon ends, upstream of the position 9 
where the inverse-PCR oligonucleotides annealed e.g. if using the TetW-Tn5 10 
transposon previously described for bifidobacteria, sequencing can be performed using 11 
oligonucleotides pMOD-fw-seq 5′-GCCAACGACTACGCACTAGCC-3′ and pMOD-rev-seq 12 
5′-GAGCCAATATGCGAGAACACC-3′ (14). 13 
Notes 14 
1. Molecular biology grade reagents need to be used for transposon construction and 15 
transposase-transposon assembly. Standard caution to prevent nuclease 16 
contamination of transposon DNA preparation needs to be taken (use molecular 17 
biology grade reagents, gloves and filter tips). 18 
2. Virtually any piece of DNA can be included into a transposon, in between the mosaic 19 
ends recognized by the corresponding transposase. For further instructions and 20 





3. If using pMOD2-TetW grow the E. coli host cells harbouring the vector in LB 1 
supplemented with 10 μg ml-1 of tetracycline. Grow E. coli cultures into sterile tubes, 2 
ensuring to leave a sufficient empty space in the tubes to allow for appropriate 3 
aeration during incubation. Grow the cultures by incubating them overnight at 37ºC in 4 
a rotary shaker (200 r.p.m.). 5 
4. D-Lactose might need to be replaced by an alternative carbon source depending on 6 
the particular needs of the strain used (14). In order facilitate preparation of a 10 % 7 
stock solution of D-lactose, the suspension might need to be warmed up at 37ºC, e.g. 8 
incubate it in a water bath at 37ºC for 5 minutes and then vortex until the 9 
carbohydrate is fully dissolved in the suspension. Then filter sterilize (0.2 μm pore 10 
filters). 11 
5. After autoclaving agar containing media, leave the bottles to cool down to 12 
approximately 50ºC before adding the antibiotic solution as it might be heat labile. 13 
Gently mix the medium bottles and pour the plates. 14 
6. Discard the tetracycline solution stored at -20ºC if precipitation is observed. 15 
7. Alternative methods to purify the PCR-amplified transposon so as to eliminate salts, 16 
and excess of nucleotides and primers, can be used (for example polyethylene glycol 17 
precipitation or standard ethanol precipitation).  18 
8. When designing a new customized transposon construct, ensure the absence of 19 
PshAI or PvuII internal restriction sites in the constructed transposon. Alternatively, 20 





possible to PCR-amplify the transposon piece of DNA by employing a single 1 
phosphorylated oligonucleotide, annealing with the Tn5 mosaic end (5'-2 
CTGTCTCTTATACACATCT-3'). If the transposon is amplified in this way from the pMOD-3 
derived constructs, there is no need to trim the transposon ends with PshAI or PvuII 4 
restriction. 5 
9. Avoid the presence of bubbles in the sample dispensed in the electroporation 6 
cuvette. 7 
10. Time of incubation following electroporation might need to be adjusted depending 8 
on the strains used and transformation efficiencies. Longer times increase the number 9 
of antibiotic resistant colonies obtained, but this may be the result of growth rather 10 
than increased transposition efficiency. 11 
11. When optimizing transposon mutagenesis strategies in new strains, it is critical to 12 
achieve high transformation efficiencies and to guarantee that the antibiotic selective 13 
marker included within the transposon is efficiently expressed in the selected host and 14 
allows accurate and reliable selection for transposition events. Type I and Type II 15 
endogenous restriction-modification systems encoded in the host genome have been 16 
demonstrated as key bottlenecks limiting transformation efficiencies in bifidobacteria 17 
(4, 9). Therefore, if the (recognition sites of the) restriction-modification systems of the 18 
host genome are known, it is advisable to avoid the presence of the corresponding 19 





12. For alternative procedures to simultaneously identify transposon insertion points 1 
in large collections of transposon insertion mutants, see (18). 2 
13. Multiple procedures have been available in order to extract DNA from 3 
Bifidobacterium cells. As a general guideline, cell pellets obtained from 6 ml of 4 
Bifidobacterium cells grown overnight need to be lysed enzymatically by suspending 5 
the cell pellets into TE buffer supplemented with lysozyme (30 mg ml-1) and 6 
mutanolysin (5 U ml-1) and incubated for at least 30 minutes at 37ºC. Then proceed 7 
with DNA purification procedures either using column-based kits or standard 8 
phenol/chloroform purification coupled to ethanol precipitation (19).  9 
14. In the inverse-PCR programme, include a long elongation time in each cycle (at 10 
least 8 minutes). 11 
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Figure Legends 16 
Figure 1. Schematic overview of the main steps required to create transposon insertion 17 
mutants in bifidobacteria, by using EZ-tn5 transposome complexes and a customized 18 
tetracycline resistant Tn5- transposon encompassing a TetW casette.  19 
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